​

Mural Oncology Stock (NASDAQ:MURA)

OwnershipFinancialsChart
Mural Oncology by TradingView

Previous Close

$2.04

52W Range

$0.95 - $4.74

50D Avg

$2.08

200D Avg

$2.37

Market Cap

$35.38M

Avg Vol (3M)

$170.82K

Beta

2.96

Div Yield

-

MURA Company Profile

Mural Oncology Plc, a clinical-stage company, is dedicated to discovering and advancing immune-based therapies for individuals battling cancer. Its primary drug candidate, nemvaleukin alfa, is currently under investigation as a standalone agent for mucosal melanoma and in partnership with pembrolizumab for platinum-resistant ovarian cancer. Additionally, the company is progressing projects centered on modified interleukin-18 and tumor-specific interleukin-12. Incorporated in 2017, Mural Oncology maintains its headquarters in Dublin, Ireland. By November 15, 2023, the company had transitioned from being a subsidiary of Alkermes plc.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

IE

Employees

116

IPO Date

Nov 16, 2023

Website

MURA Performance

MURA Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income-$-194.64M$-195.15M
Net Income$-128.51M$-207.45M$-200.03M
EBITDA-$-192.72M$-183.38M
Basic EPS$-7.58$-12.43$-11.99
Diluted EPS$-7.58$-12.43$-11.99

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
LIMNLiminatus Pharma, Inc. Class A Common Stock
VERUVeru Inc.
EVAXEvaxion Biotech A/S
JSPRJasper Therapeutics, Inc.
BTAIBioXcel Therapeutics, Inc.
VRCAVerrica Pharmaceuticals Inc.
SABSSAB Biotherapeutics, Inc.
BCABBioAtla, Inc.
GBIOGeneration Bio Co.
ATHEAlterity Therapeutics Limited